BioAge Labs appears to be a pre-commercial biotechnology story in which milestone-linked revenue of roughly $2.5M per quarter has failed to offset an operating loss that widened to -$29.3M in Q2 2026, driven by R&D spending of $24.4M and rising stock-based compensation of $4.3M per quarter.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.73-7.4% vs -$0.68 | $298,000-79.8% vs $1M |
Q3 2026 Aug 6, 2026 | -$0.58+4.5% vs -$0.61 | $2M+63.7% vs $1M |
Q2 2026 May 8, 2026 | -$0.52+18.7% vs -$0.64 | $3M+155.9% vs $1M |
Q2 2026 Mar 24, 2026 | -$0.72+13.3% vs -$0.83 | $3M+119.9% vs $1M |
BioAge Labs, Inc. (BIOA) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.56 per share a year ago.
First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027
BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioAge Labs (NASDAQ: BIOA - Get Free Report) and Royalty Pharma (NASDAQ: RPRX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability. Analyst Recommendations This is a summary of recent
Benchmark BIOA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BioAge Labs Inc. (BIOA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.34 | $201.05M | -2.27 | — | -1253.6% | -31.42% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $192.28 | $40.88B | -22.10 | — | -946.82% | -91.93% | — | |
| $100.61 | $6.55B | 25.50 | 0.5% | 17.28% | 21.72% | — | |
| $112.28 | $7.7B | -40.00 | 45.83% | -69.03% | -83.68% | — | |
| $3.82 | $229.72M | -0.84 | 8.72% | -119.87% | -106.94% | — |
BioAge Labs Inc. (BIOA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
BioAge Labs Inc. (BIOA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 12, 2026·SEC
May 8, 2026·SEC
Get notified when BIOA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioAge Labs Inc. (BIOA) stock FAQ — growth, dividends, profitability & financials explained
BioAge Labs Inc. (BIOA) reported $8.6M in revenue over the trailing twelve months. Revenue was $9.0M in fiscal year 2025.
BioAge Labs Inc. (BIOA) grew revenue by 45.3% over the trailing twelve months, compared with the twelve months before.
No. BioAge Labs Inc. (BIOA) reported a net loss of $107.8M over the trailing twelve months.
BioAge Labs Inc. (BIOA) had a return on equity (ROE) of -31.4% over the trailing twelve months. A negative ROE means the company lost money over the period.
BioAge Labs Inc. (BIOA) had negative free cash flow of $103.0M over the trailing twelve months.
